<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="293">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218047</url>
  </required_header>
  <id_info>
    <org_study_id>CONTINUATION-PV</org_study_id>
    <secondary_id>2014-001357-17</secondary_id>
    <nct_id>NCT02218047</nct_id>
  </id_info>
  <brief_title>AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.</brief_title>
  <acronym>CONTI-PV</acronym>
  <official_title>An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOP Orphan Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaEssentia (Co-Sponsor for USA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AOP Orphan Pharmaceuticals AG</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Bulgaria: Ministry of Health</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: Ministry of Health, Social and Family Affairs</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic
      increase of red blood cells and frequently also of white blood cells. The &quot;thickening&quot; of
      the blood in relation with a modified function of the cells has several consequences like
      increased blood pressure, pruritus of the skin, fatigue, disturbed blood circulation in the
      brain as well as fingers and toes and an increased risk of arterial and venous thrombosis
      (thrombosis is the formation of a blood clot in a vessel); like stroke, cardiac infarction,
      deep vein thrombosis in the legs. In case of a strong increase of platelets there is an
      additional risk of bleedings. As the disease progresses the size of spleen and liver
      increased in most cases and the bone marrow shows signs of fibrosis. In some cases of PV a
      progression at a later time point to a leukemia (increased formation of white blood cells)
      can occur.

      The aim of this study is to show that the study drug AOP2014 (pegylated proline interferon
      alpha-2b) has the long term efficacy and safety in controlling the disease. Response to the
      treatment is measured by several blood parameters as well as size of the spleen.

      Interferon-alpha has been shown to be effective in controlling the blood parameters by
      immunologically influencing the blood building cells. This can lead to a suppression of the
      disease-causing stem cells and help healthy stem cells to proliferate. Through this
      mechanism it is possible that Interferon-alpha can avoid long-term damaging effects of the
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, single arm, open-label continuation of the PROUD-PV study performed in
      adults diagnosed with Polycythemia Vera (PV). Only the patients who received AOP2014 in the
      primary study, PROUD-PV, and completed the end of study visit will be enrolled into this
      continuation study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Hct level of 40 - 42% without phlebotomies.</measure>
    <time_frame>1.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]&lt;45%, platelets [PLTs]&lt;400 x 109/L and leukocytes [WBCs]&lt;10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Pegylated-Proline-interferon alpha-2b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated-Proline-interferon alpha-2b</intervention_name>
    <description>Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]&lt;45%, platelets [PLTs]&lt;400 x 109/L and leukocytes [WBCs]&lt;10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.</description>
    <arm_group_label>Pegylated-Proline-interferon alpha-2b</arm_group_label>
    <other_name>AOP2014</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who completed the 12 months AOP2014 treatment arm of the PROUD-PV study and
             at the &quot;end-of-treatment visit&quot; (EoT) of the PROUD-PV study who fulfill at least one
             of the following criteria:

               -  normalization of at least two out of three main blood parameters (Hct, PLTs and
                  WBCs) if these parameters were moderately increased (Hct&lt;50%, WBC&lt;20 x 109/L,
                  PLTs&lt;600 x 109/L) at baseline of the PROUD-PV study, OR

               -  &gt;35% decrease of at least two out of three main blood parameters (Hct, PLTs and
                  WBCs) if these parameters were massively increased (Hct&gt;50%, WBCs&gt;20 x 109/L,
                  PLTs&gt;600 x 109/L), at baseline of the PROUD-PV study, OR

               -  normalization of spleen size, if spleen was enlarged at baseline of the PROUD-PV
                  study, OR

               -  otherwise a clear, medically verified benefit from treatment with AOP2014 (e.g.
                  normalization of disease-related micro-vasculatory symptoms, substantial
                  decrease of JAK2 allelic burden).

          2. Signed written ICF.

        Exclusion criteria:

        Withdrawal criteria, as specified in the PROUD-PV study, which mandate treatment
        discontinuation:

          1. Non-recovery from the AOP2014 related toxicities to the grade (usually, Grade I)
             which allows continuation of the treatment.

          2. HADS score of 11 or higher on either or both of the subscales, and /or development or
             worsening of the clinically significant depression or suicidal thoughts.

          3. Progressive and clinically significant increase of liver enzyme levels despite dose
             reduction, or if such increase is accompanied by increased bilirubin level, any signs
             or symptoms of a clinically significant autoimmune disease.

          4. Clinically significant development of a new ophthalmologic disorder, or worsening of
             a pre-existing one, during the study.

          5. Loss of efficacy of AOP2014 or any comparable situation where no further benefits of
             treatment continuation are expected by the investigator.

        The main efficacy evaluation criterion will be disease response defined as Hct&lt;45% without
        phlebotomy (at least 3 months since the last phlebotomy), PLTs&lt;400 x 109/L, WBCs&lt;10 x
        109/L, and normal spleen size.

        The main efficacy endpoint will be the maintenance rate of disease response at assessment
        visits (every three months).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Gisslinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med Uni Wien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oleh Zagrijtschuk, MD</last_name>
    <phone>+43-1-5037244 - 76</phone>
    <email>oleh.zagrijtschuk@aoporphan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Zörer, PhD</last_name>
    <phone>+43-1-5037244 - 46</phone>
    <email>michael.zoerer@aoporphan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LKH Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Werner Linkesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ella Willenbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabethinen Hospital Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veronika Buxhofer-Ausch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salzburg Regional Hospital</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Richard Greil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ernst Schloegl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heinz Gisslinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sonja Burgstaller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;, Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pencho Georgiev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georgi Mihaylov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Sveta Marina&quot;, Varna</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liana Gercheva-Kyuchukova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine</name>
      <address>
        <city>Vratsa</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Liliya Sivcheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiri Mayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Petr Dulicek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jiri Schwarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olga Cerna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ivana Hochova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Paoli-Calmettes</name>
      <address>
        <city>Marseilles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jerome Rey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Jacques Kiladjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center CIC</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lydia Roy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aachen University Hospital, Medical Clinic IV</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steffen Koschmieder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dominik Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Uwe Platzbecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Istvan and St Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tamas Masszi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arpad Illes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Janos Jakucs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor County Teaching Hospital</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miklos Egyed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zita Borbenyi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Careggi University Hospital</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alessandro Vannucchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mario Cazzola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Slawomira Kyrcz-Krzemien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital in Cracow</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleksander Skotnicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No.1 in Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Soroka-Wojtaszko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fryderyk Chopin Provincial Specialized Hospital</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jolanta Starzak-Gwozdz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Municipal Specialist Hospital</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Malgorzata Calbecka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusion Medicine</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Krzysztof Warzocha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Clinical County Hospital Brasov</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emanuil Gheorghita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bucharest University Emergency Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horia Bumbea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coltea Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicoleta Berbec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Prof. Dr. Ion Chiricuta&quot; Institute of Oncology,</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrei Cucuianu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baranov Republican Hospital</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexander Myasnikov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samara Kalinin Regional Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viktor Rossiev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Boris Afanasyev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Komi Republican Oncology Center</name>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Irina Sokolova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tula Regional Clinical Hospital</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elena Volodicheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vera Yablokova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital with Outpatient Clinic F.D. Roosevelt</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anna Vallova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Cyril and Metod University Hospital Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mikulas Hrubisko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francisco Cervantes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carles Besses Raebel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center</name>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Halyna Pylypenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Multispecialty Clinical Hospital #4</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Polina Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Center for Radiation Medicine, Institute of Clinical Radiology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Serhii Klymenko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zvenyslava Masliak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>O.F. Herbachevskyi Regional Clinical Hospital</name>
      <address>
        <city>Zhytomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tamila Lysa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 12, 2015</lastchanged_date>
  <firstreceived_date>August 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pegylated-Proline-interferon alpha-2b (AOP2014)</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>PROUD-PV</keyword>
  <keyword>CONTINUATION-PV</keyword>
  <keyword>AOP Orphan</keyword>
  <keyword>Polycythemia</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Myeloproliferative Disorders</keyword>
  <keyword>Bone Marrow Diseases</keyword>
  <keyword>Interferon-alpha</keyword>
  <keyword>Peginterferon alfa-2b</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
